Full-Time
Posted on 10/25/2024
Develops cell therapy for chronic kidney disease
Expert
Winston-Salem, NC, USA
You match the following ProKidney's candidate preferences
Employers are more likely to interview you if you match these preferences:
ProKidney focuses on developing a new treatment for Chronic Kidney Disease (CKD) using a cell therapy called rilparencel. This therapy aims to help preserve kidney function in patients with advanced CKD, potentially delaying or eliminating the need for dialysis, which is a common and life-changing procedure for many patients. ProKidney is currently in the late stages of clinical trials, and early results indicate that rilparencel may effectively maintain kidney function. What sets ProKidney apart from its competitors is its specific focus on CKD and its unique approach to treatment through cell therapy, targeting a significant and underserved patient population. The company's goal is to provide a new therapeutic option that can improve the quality of life for millions of CKD patients, ultimately transforming their treatment experience.
Company Size
51-200
Company Stage
IPO
Total Funding
$559.3M
Headquarters
Winston-Salem, North Carolina
Founded
2015
Help us improve and share your feedback! Did you find this helpful?
WINSTON-SALEM, N.C., Jan. 07, 2025 (GLOBE NEWSWIRE) - ProKidney Corp. (Nasdaq: PROK) ("ProKidney"), a late clinical-stage biotech company focused on the development of a first-in-class cell therapy candidate for chronic kidney disease (CKD), today announced that ProKidney's CEO, Bruce Culleton, M.D., will present at the 43rd Annual J.P. Morgan Healthcare Conference.
In June 2023, ProKidney announced that the company planned to invest $485 million in a Greensboro biomedical factory that would create roughly 330 jobs - with those jobs averaging just under $75,000 a year.
ProKidney's purchasing the buildings from Breit SE Industrial Propco, also known as Blackstone Real Estate Income Trust.
ProKidney had previously planned to expand operations into Greensboro.
Less than six months after joining the company, Dr. Bruce Culleton was appointed CEO of ProKidney, a regenerative medicine that made one of the largest manufacturing investments in Triad history.
On Sept. 8, ProKidney confirmed it will expand its Winston-Salem laboratory, manufacturing and office operations by making a $21 million capital investment and creating 50 jobs by 2027.
ProKidney Corp Announces Successful Closing of $140 Million Public Offering and Registered Direct Offering<br/>ProKidney Corp, a leading late clinical-stage cellular therapeutics company focused on chronic kidney disease, has recently completed a significant financial milestone. The company has successfully closed a public offering and concurrent registered direct offering, raising a total of $140 million.<br/>In the public offering, ProKidney sold 46,886,452 Class A ordinary shares to the public at a price of $2.42 per share. This includes an additional 4,142,232 Class A ordinary shares that were sold as a result of the underwriters exercising their option to purchase additional shares. The total value of the shares sold in the public offering, before applicable underwriting discounts and commissions, amounts to $113.5 million.<br/>
ProKidney (NASDAQ: PROK) unveils $125M public offering to boost clinical trials & R&D. Interested investors include entities tied to the chairman. Learn more.
ProKidney LP (“ProKidney”), a leading clinical-stage cellular therapeutics company focused on chronic kidney disease (“CKD”), has entered into a defin
In mid-2023, ProKidney Corp., a medical tech company based out of Winston-Salem, announced that it would be opening a big facility in Greensboro and bringing 330 jobs to the city.